# A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

> **NCT05658562** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tanabe Pharma Corporation** · enrollment: 46 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** MT-2111

## Key facts

- **NCT ID:** NCT05658562
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-30
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05658562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05658562, "A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05658562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*